News and Trends 12 Jun 2017
Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies
Targovax has raised €21M (NOK200M) in a private placement, which the biotech will use to fund data read-outs from clinical trials and CMC development. Targovax, based in Oslo, is developing a number of immunotherapies for treatment-resistant tumors. The biotech’s pipeline is based on its two platforms, ONCOS, an oncolytic virus, which is being developed to treat melanoma, […]